Zobrazeno 1 - 10
of 2 453
pro vyhledávání: '"mirabegron"'
Publikováno v:
Beni-Suef University Journal of Basic and Applied Sciences, Vol 13, Iss 1, Pp 1-10 (2024)
Abstract Background Inserting ureteral stents is a routine intervention that often results in problems. The cornerstone for treating stent-related symptoms is pharmacological therapy. This study was conducted to evaluate and to compare the effectiven
Externí odkaz:
https://doaj.org/article/2c3cbbfcbded41c685953d618e09d877
Autor:
Xiangxiang Zhang, Yinhui Mao, Yang Liu, Jilei Sun, Juntao Sun, Chenli Pan, Zhuo Wang, Zhitao Wei, Yong Yang
Publikováno v:
Frontiers in Surgery, Vol 11 (2024)
The prevalence and severity of overactive bladder increase with age, and mirabegron is an approved treatment for this condition. This meta-analysis systematically evaluated the efficacy and safety of mirabegron compared with placebo for overactive bl
Externí odkaz:
https://doaj.org/article/49cdb95bc6ae4710b6e13ad619ca1759
Autor:
Roger Bentanachs, Lluïsa Miró, Rosa M. Sánchez, Patricia Ramírez-Carrasco, Concepció Amat, Marta Alegret, Anna Pérez, Núria Roglans, Juan C. Laguna
Publikováno v:
Biomedicine & Pharmacotherapy, Vol 177, Iss , Pp 117067- (2024)
Background and aims: Drugs resolving steatotic liver disease (SLD) could prevent the evolution of metabolic dysfunction associated SLD (MASLD) to more aggressive forms but must show not only efficacy, but also a high safety profile. Repurposing of dr
Externí odkaz:
https://doaj.org/article/5df01807c6744dbc8f567596638bf3f0
Autor:
A. E. Muderrisoglu, A. Ciotkowska, B. Rutz, S. Hu, S. Qian, A. Tamalunas, C. G. Stief, M. Hennenberg
Publikováno v:
Frontiers in Pharmacology, Vol 15 (2024)
IntroductionMirabegron is available for treatment of overactive bladder (OAB). However, mechanisms underlying symptom improvements and long-term effects on bladder smooth muscle cells are uncertain. Contractility and growth of bladder smooth muscle c
Externí odkaz:
https://doaj.org/article/3dabeb2b799941a09f84a4df421513e9
Autor:
Sheng-Mou Hsiao
Publikováno v:
Scientific Reports, Vol 14, Iss 1, Pp 1-8 (2024)
Abstract Persistence is important for the success in the treatment of women with overactive bladder syndrome (OAB). We aimed to identify the predictors of non-persistence in women with OAB after first-line medical treatment. All consecutive women wit
Externí odkaz:
https://doaj.org/article/601902427fc14e53b4376b01e5a2cb7e
Publikováno v:
Frontiers in Neuroscience, Vol 18 (2024)
ObjectiveTo observe the efficacy and safety of pelvic floor magnetic stimulation (PFMS) combined with mirabegron in female patients with refractory overactive bladder (OAB) symptoms.Patients and methodsA total of 160 female patients with refractory O
Externí odkaz:
https://doaj.org/article/585c321b30e041afbcdd6fcaad723809
Autor:
Rahma Almallah, Hani Almukhtar
Publikováno v:
المجلة العراقية للصيدلة, Vol 20, Iss Supplementary Issue 1, Pp 195-200 (2023)
Background: Mirabegron operates through a distinct mechanism compared to antimuscarinic agents. Its activation of β3-adrenoceptors results in the relaxation of the bladder during the filling phase of micturition. The activation of β3-adrenoceptors,
Externí odkaz:
https://doaj.org/article/035db26e95724709b687dd7f6e2f608f
Autor:
Paula Soria-Chacartegui, Patricia Cendoya-Ramiro, Eva González-Iglesias, Samuel Martín-Vílchez, Andrea Rodríguez-Lopez, Gina Mejía-Abril, Manuel Román, Sergio Luquero-Bueno, Dolores Ochoa, Francisco Abad-Santos
Publikováno v:
Pharmaceutics, Vol 16, Iss 8, p 1077 (2024)
Mirabegron is a drug used in overactive bladder (OAB) treatment. Genetic variation in pharmacogenes might alter its pharmacokinetics, affecting its efficacy and safety. This research aimed to analyze the impact of genetic variation on mirabegron phar
Externí odkaz:
https://doaj.org/article/16ce8909e59643bea89e1a8908121bfe
Autor:
Cătălin Pricop, Carina Alexandra Bandac, Marius Ivanuță, Daniel Rădăvoi, Viorel Jinga, Dragoş Puia
Publikováno v:
Journal of Clinical Medicine, Vol 13, Iss 14, p 4278 (2024)
Introduction: The application of double-J ureteral stents in urology is widespread, but their use is often accompanied by complications and bothersome symptoms, affecting patients’ quality of life (QoL). While various medications have been tested f
Externí odkaz:
https://doaj.org/article/a30b0c12068a4980882b2461b77fe71b
Publikováno v:
International Journal of Molecular Sciences, Vol 25, Iss 13, p 7468 (2024)
The β3-adrenoceptor agonist mirabegron is available for the treatment of storage symptoms of overactive bladder, including frequency, urgency, and incontinence. The off-target effects of mirabegron include binding to α1-adrenoceptors, which are cen
Externí odkaz:
https://doaj.org/article/0c1ae26c70194cbfbb6eaa9345adfc9d